Fitzgerald Joseph Michael, EVP & Group President of Cardiology at Boston Scientific, has filed 69 Form 4 transactions, all in BSX stock. The pattern is overwhelmingly skewed toward the sell side: his open-market sales total roughly $31.2 million, against just $4,514.60 in open-market purchases. The recent activity reinforces that bias—over the past year, he has executed eight open-market sales with zero buys, while the bulk of his acquisition value ($3.0 million) came from option exercises and equity awards, which are compensation events rather than discretionary purchases.
The most concentrated selling occurred in late 2025 and early 2026. On November 3, 2025, he sold shares in three separate transactions totaling about $4.97 million, following an option exercise of $1.31 million. That came after an October 1, 2025 sale of roughly $4.92 million, also paired with a $1.31 million exercise, and a September 2, 2025 sale of $5.27 million. The largest single sale was $5.23 million on August 1, 2025. His most recent open-market sale was November 3, 2025; since then, filings show only automatic transactions—shares withheld to cover taxes (totaling about $2.87 million in February 2026), option exercises, and grants—plus a $3.0 million conversion event on July 31, 2026.
The data shows a consistent, recurring pattern of large, periodic open-market sales aligned with option exercises, typical of a senior executive monetizing vested equity. The absence of any recent open-market purchases, combined with the multi-million-dollar sale cadence, indicates a clear net-selling posture over the covered period.
AI-assisted summary